Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study

Derya Köseoğlu Salih Süha Koparal Ozden Ozdemir Baser Dilek Berker

Published in: Turkish journal of medical sciences (2021)

This study showed improvement in lipid profile and hsCRP levels with exenatide treatment. We also showed decrease in both visceral fat volume and subcutaneous fat thickness. We demonstrated significant decrease in liver enzymes with significant decrease in liver diameter. These findings support the use of exenatide in patients with NAFLD and T2DM. Additionally, this study showed that exenatide treatment given twice daily reduces CIMT in obese T2DM patients.

Keyphrases

obese patients
cardiovascular risk factors
adipose tissue
bariatric surgery
end stage renal disease
metabolic syndrome
ejection fraction
chronic kidney disease
newly diagnosed
roux en y gastric bypass
weight loss
physical activity
fatty acid
prognostic factors
skeletal muscle
combination therapy
glycemic control